Table 2.
Available FDA-approved biologics used in the treatment of hidradenitis suppurativa, psoriasis, pyoderma gangrenosum, toxic epidermal necrolysis, rosacea, and allergic contact dermatitis
| Disease | Target | Drug Name | ClinicalTrials.gov Identifier | Phase 4 Recruitment Status | Adverse Reactions |
|---|---|---|---|---|---|
| HS | TNF-α | Adalimumab | NCT02808975 | Complete | Infection, URI, Antibody development, Injection site reaction, Positive ANA titer, Headache, Skin rash, Increased creatine phosphokinase |
| PP | IL-17A | Secukinumab | NCT02798211 | Complete | Infection, URI |
| IL-17A | Ixekizumab | NCT03151551 | Complete | Infection, URI, Antibody development, Injection site reaction, Neutropenia | |
| IL-17 receptor A | Brodalumab | NCT03403036 | Complete | Infection, URI | |
| IL-12/IL-23 | Ustekinumab | NCT01511315 | Complete | Infection, URI, Antibody development | |
| IL-23 | Tildrakizumab | NCT04271540 | Recruiting | Infection, URI | |
| IL-23 | Risankizumab | NCT04340076 | Recruiting | Infection, URI, Antibody development | |
| IL-23 | Guselkumab | NCT03573323 | Completed | Infection, URI | |
| TNF-α | Adalimumab | NCT01265823 | Complete | Infection, URI, Antibody development, Injection site reaction, Positive ANA titer, Headache, Skin rash, Increased creatine phosphokinase | |
| TNF-α | Etanercept | NCT00967538 | Complete | Infection, URI, Antibody development, Injection site reaction, Positive ANA titer, Skin rash, Diarrhea | |
| TNF-α | Infliximab | NCT00779675 | Complete | Infection, URI, Antibody development, Positive ANA titer, double-stranded DNA antibody development, Infusion related reaction, Headache, Nausea, Abdominal pain, Abscess, Increased serum alanine aminotransferase | |
| TNF-α | Certolizumab pegol | NCT02326298 | Complete | Infection, URI, Antibody development, Nausea | |
| PG | No FDA approved biologics | ||||
| TEN | No FDA approved biologics | ||||
| RSA | No FDA approved biologics | ||||
| ACD | No FDA approved biologics | ||||
Listed for each drug is the drug's target, identifier number, recruitment status as of October 2021, and common adverse reactions with incidences indicated in the most recent FDA label.
ACD, allergic contact dermatitis; ANA, antinuclear antibody; HS, hidradenitis suppurativa; IL, interleukin; PG, pyoderma gangrenosum; PP, plaque psoriasis; RSA, rosacea; TNF-α, tumour necrosis factor alpha; URI, upper respiratory infection.